Product Description: Vobramitamab is a humanized B7-H3 monoclonal antibody (mAb). Vobramitamab conjugated with prodrug seco-DUBA (HY-132180A) via a cleavable linker, to form antibody-drug conjugate (ADC), the MGC018[1].
Applications: Cancer-programmed cell death
Formula: N/A
References: [1]Brignole C, et al. Anti-tumor activity of vobramitamab duocarmazine (MGC018), an investigational duocarmycin-based anti-B7-H3 antibody-drug conjugate (ADC), in preclinical neuroblastoma models[J]. Cancer Research, 2023, 83(7_Supplement): 2981-2981.
CAS Number: 2490556-50-6
Molecular Weight: N/A
Compound Purity: 99.67
Research Area: Cancer
Solubility: 10 mM in DMSO/H2O
Target: ADC Antibody